Chemotherapy-Induced Alopecia in Breast Cancer Patients: Treatment-Specific Incidence and Risk of Persistent Hair Loss

TL;DR

This paper reviews how different breast cancer chemotherapy regimens cause hair loss, finding that some treatments lead to severe and persistent alopecia, highlighting the need for better patient care and reporting.

Contribution

The study provides a detailed analysis of chemotherapy regimen-specific risks for persistent alopecia in breast cancer patients.

Findings

Anthracycline- and taxane-based treatments are linked to the highest rates of severe and persistent hair loss.

Cyclophosphamide combined with doxorubicin causes up to 93% incidence of acute alopecia.

Persistent alopecia occurs in up to 67% of patients treated with doxorubicin-based regimens.

Abstract

Chemotherapy-induced alopecia is one of the most visible and emotionally distressing side effects of breast cancer treatment. Although it is often considered temporary, growing evidence suggests that some patients experience persistent hair loss long after therapy completion. In this review, we examined published studies reporting the incidence and severity of alopecia across commonly used chemotherapy regimens for breast cancer. Our analysis shows that anthracycline- and taxane-based treatments are associated with the highest rates of severe hair loss, while other agents such as eribulin, capecitabine, vinorelbine, and gemcitabine tend to cause lower rates of alopecia. These findings highlight the importance of patient counseling, risk assessment, and survivorship care for patients undergoing breast cancer treatment.

Chemotherapy-induced alopecia (CIA) is one of the most common and visible toxicities of breast cancer treatment, yet its true incidence, severity, and long-term outcomes remain inconsistently reported. Although CIA is frequently cited as affecting approximately 65% of patients and persistent alopecia has historically been considered uncommon (1–15%), emerging data suggest a substantially greater burden. We conducted a scoping review of PubMed, EMBASE, SCOPUS, and Cochrane databases to synthesize regimen-specific evidence on the incidence, severity, and persistence of CIA in breast cancer patients. Anthracycline- and taxane-based regimens were associated with the highest risk, with severe alopecia reported in more than 70% of patients and rates approaching 90–100% in combination regimens. Cyclophosphamide further amplified acute CIA when combined with doxorubicin, with reported incidence up to 93%. In contrast, capecitabine and vinorelbine were consistently associated with lower alopecia incidence. Importantly, CIA was not uniformly reversible. Persistent CIA (pCIA) occurred in up to 67% of patients treated with doxorubicin-based regimens and nearly 50% of those receiving docetaxel combinations, substantially higher than historically reported. Despite its high frequency and potential permanence, CIA remains underreported in oncology trials and insufficiently addressed in survivorship care. Recognizing CIA as both an acute toxicity and a potential long-term survivorship concern underscores the need for standardized reporting, longitudinal follow-up, and development of effective preventive strategies in breast cancer care.